基于影像状态的基因导向双联抗血小板治疗用于短暂性脑缺血发作和轻型卒中:CHANCE-2试验亚组分析
该研究纳入CHANCE-2试验中5796例有DWI数据的患者,比较替格瑞洛/阿司匹林与氯吡格雷/阿司匹林在DWI阳性与阴性患者中的疗效。DWI阳性患者3个月卒中复发风险为8.1%,高于DWI阴性者的2.2%;在DWI阳性患者中,替格瑞洛/阿司匹林较氯吡格雷/阿司匹林降低卒中风险(HR=0.65,95%CI 0.52-0.80,p<0.001),交互作用p=0.049。两组中重度出血风险相似。
要点
- DWI阳性患者3个月卒中复发风险为8.1%,高于DWI阴性者的2.2%。
- DWI阳性患者中替格瑞洛/阿司匹林较氯吡格雷/阿司匹林降低卒中风险(HR=0.65)。
- 不同DWI组间中重度出血风险相似。
核心结论
- 在DWI阳性患者中,替格瑞洛/阿司匹林较氯吡格雷/阿司匹林降低3个月卒中复发风险,且与DWI状态存在显著交互作用(交互作用p=0.049)。
- 作者认为未来临床研究和实践中,在确定基因导向双联抗血小板治疗最佳候选者前应重视影像学评估。
研究设计与样本
- CHANCE-2试验的亚组分析,纳入该试验中有DWI数据的患者,按DWI所见分为有和无急性梗死两组。
- 共纳入5796例(占CHANCE-2试验6412例的90.4%),其中4369例(75.4%)DWI显示急性梗死。
- 主要疗效结局为3个月随访内卒中复发,安全结局为中重度出血。
主要发现
- DWI阳性患者3个月随访内卒中复发风险为8.1%,高于DWI阴性患者的2.2%。
- DWI阳性患者中,替格瑞洛/阿司匹林较氯吡格雷/阿司匹林降低卒中风险(HR=0.65,95%CI 0.52-0.80,p<0.001)。
- DWI阴性患者中,替格瑞洛/阿司匹林与氯吡格雷/阿司匹林相比卒中风险无显著差异(HR=1.22,95%CI 0.55-2.72,p=0.63)。
- DWI状态与治疗分配存在显著交互作用(交互作用p=0.049)。
- 不同DWI组中,替格瑞洛/阿司匹林与氯吡格雷/阿司匹林的中重度出血风险相似。
临床怎么用
- 作者认为未来临床研究和实践中,在确定基因导向双联抗血小板治疗最佳候选者前应重视影像学评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study was performed to investigate whether ticagrelor/aspirin versus clopidogrel/aspirin can further reduce the residual risk of stroke recurrence in patients with positive diffusion-weighted imaging (DWI) in the High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial. METHODS: Patients with DWI data in the CHANCE-2 trial were included and divided into those with and without acute infarction according to their DWI findings. The primary efficacy outcome and safety outcome were stroke recurrence and moderate to severe bleeding within 3 months of follow-up, respectively. RESULTS: Of the 6,412 patients enrolled in the CHANCE-2 trial, 5,796 (90.4%) patients with DWI data were included in the subgroup analysis. A total of 4,369 patients (75.4%) had an acute infarction on DWI. Patients with positive DWI had higher risk of recurrent stroke (8.1%) than those without infarction (2.2%) within 3-month follow-up. Compared with clopidogrel/aspirin, ticagrelor/aspirin was associated with lower risk of stroke in patients with positive DWI (hazard ratio [HR] = 0.65, 95% confidence interval [CI] = 0.52-0.80, p < 0.001) than in those negative DWI (HR = 1.22, 95% CI = 0.55-2.72, p = 0.63), with a significant interaction association (p for interaction = 0.049). The risk of moderate to severe bleeding was similar between ticagrelor/aspirin and clopidogrel/aspirin treatment in the different groups. INTERPRETATION: Our study demonstrates that imaging evaluation should be emphasized before targeting the best candidates for genotype-guided dual antiplatelet therapy in future clinical research and practice. ANN NEUROL 2023;93:783-792.
引用
- Jing J, Xie X, Johnston SC, et al. Genotype-Guided Dual Antiplatelet Use for Transient Ischemic Attack and Minor Stroke by Imaging Status: Subgroup Analysis of the CHANCE-2 Trial. Ann Neurol. 2023. PMID: 36571569. doi:10.1002/ana.26589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。